Yuhan Corp: royalties from lung cancer drug soar…technology transfer of allergy treatment draws attention
Predicted impact: Medium· Actual: +4.0% vs sector, volume 2.7× normal (5 trading days)
Lazertinib sales above $300M quarterly; meaningful earnings driver, size vs revenue unclear.